FierceBiotechOriginal article
{"a":[{"_":"Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies","$":{"href":"/biotech/jazz-plays-epilepsy-intentions-132b-acquisition-actio-biosciences","hreflang":"en"}}]}
Positive
AI Analysis
Summary
Jazz Pharmaceuticals is acquiring Actio Biosciences for $820 million upfront to expand its epilepsy treatment portfolio with a clinical-stage asset.
Importance:7/10
Sentiment:
0.60
M&Aacquisitionepilepsyclinical-stage
Related Companies
Read the original article
Published by FierceBiotech on August 10, 2026 9:48 AM